Press Release

Poxel Announces its 2016 Financial Calendar

Lyon, France, January 4, 2016 – POXEL SA (Euronext – POXEL - FR0012432516), a biopharmaceutical company focused on the development of innovative drugs to treat type 2 diabetes, today announces its schedule for the publication of financial information for 2016.

Event	Date *
2015 Full-Year Sales	January 28, 2016 – After market closes
2015 Full-Year Financial Statement	March 31, 2016 – After market closes
2016 Q1 Sales	May 5, 2016 – Before market opens
2016 Q2 Sales	July 15, 2016 – Before market opens
2016 June 30th, Financial Statement	September 12, 2016 – Before market opens
2016 Q3 Sales	October 21, 2016 – Before market opens
2016 Full-Year Sales	January 27, 2017 – Before market opens

** Subject to modification.*

About Poxel

Poxel uses its unique development expertise in metabolism to advance a pipeline of truly novel products currently focused on type 2 diabetes. Our first-in-class lead product, Imeglimin, targeting mitochondrial dysfunction, has successfully completed Phase 2 development in the US and EU and has started Phase 2b development in Japanese patients. We are advancing our second program, PXL770, a direct AMPK activator, through clinical proof-of-concept. We will generate further growth through strategic partnerships and pipeline development. (Euronext: POXEL, www.poxel.com)

Contacts

Investor relations / Media - EU/US
MacDougall Biomedical Communications
Gretchen Schweitzer or Stephanie May
smay@macbiocom.com
+ 49 89 2424 3494 or + 49 172 861 8540

Investor relations / Media – France
NewCap
Florent Alba / Nicolas Mérigeau
poxel@newcap.eu
+33 1 44 71 98 55